natgillin/translations-raw huggingface dataset:
During the treatment period (induction treatment phase comprising of R-CHOP for at most eight cycles), four patients (2 %) treated with R-CHOP, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle. 
Med obdobjem zdravljenja (faza indukcijskega zdravljenja, ki je obsegalo R-CHOP vsaj osem ciklov), so se pri štirih bolnikih (2 %), zdravljenih z R-CHOP, ki so vsi imeli kardiovaskularne dejavnike tveganja, med prvim ciklom zdravljenja pojavili trombembolični cerebrovaskularni dogodki.
PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS MabThera Alert Card for patients with non-oncology diseases 
BESEDILO OPOZORILNE KARTICE ZA BOLNIKA Z NEONKOLOŠKO INDIKACIJO Opozorilna kartica za bolnike, ki prejemajo zdravilo MabThera za neonkološke bolezni
Consideration should be given to the use of a reduced infusion rate for the first infusion in these patients or a split dosing over two days during the first cycle and any subsequent cycles if the lymphocyte count is still >25 x 109/L. 
Pri takšnih bolnikih pride v poštev manjša hitrost infundiranja že pri prvi infuziji ali razdelitev odmerka na dva dni v prvem ciklu in tudi vseh nadaljnjih ciklih, če je število limfocitov še vedno večje od 25 x 109/l.
During this time, 81% of patients, from the original placebo group received MabThera between weeks 24 and 56, under an open label extension study protocol. 
Med tem časom je 81 % bolnikov, ki so prvotno dobivali placebo, v sklopu odprte, podaljšane faze študije prejelo zdravilo MabThera med 24. in 56. tednom.
MabThera is available as a medicine given as a drip (called MabThera 100 mg or MabThera 500 mg, concentrate for solution for infusion) and as a medicine for injection under your skin (called MabThera 1400 mg or MabThera 1600 mg, solution for subcutaneous injection). 
Zdravilo MabThera je na voljo v obliki za infundiranje v veno (z imenoma MabThera 100 mg in MabThera 500 mg koncentrat za raztopino za infundiranje) in v obliki za injiciranje pod kožo (z imenom MabThera 1400 mg ali MabThera 1600 mg raztopina za podkožno injiciranje).
FU: follow-up; NR: not reached at time of clinical cut off, TNCT: time to next chemotherapy treatment; TNLT: time to next anti lymphoma treatment. 
NR: ni doseženo ob času kliničnega zaključka zbiranja podatkov (not reached), TNCT: čas do naslednje kemoterapije;
Once transferred from the vial into the syringe, the solution of MabThera subcutaneous formulation is physically and chemically stable for 48 hours at 2 °C - 8 °C and subsequently for 8 hours at 30°C in diffuse daylight. 
Ko je zdravilo preneseno iz viale v brizgo, je raztopina podkožne oblike zdravila MabThera fizikalno in kemično stabilna 48 ur pri temperaturi od 2 do 8 °C in potem 8 ur pri temperaturi 30 °C na difuzni dnevni svetlobi.
After this, you will be given MabThera as an injection under your skin. 
Pozneje lahko zdravilo MabThera dobivate v injekciji pod kožo.
with counts >10 cells/μL by month 12, increasing to 87% of patients by month 18. 
Pri večini bolnikov (81 %) se je število celic B ponovno povečalo na > 10 celic/µl do 12. meseca, do 18. meseca pa še pri večjem, 87-% deležu bolnikov.
The clinical experience of MabThera subcutaneous formulation in Non-Hodgkin's lymphoma is based on data from a phase III clinical trial (SABRINA BO22334) in patients with follicular lymphoma (FL) and a phase Ib dose-finding/dose-confirmation trial (SparkThera BP22333) in patients with FL. 
Klinične izkušnje s podkožno obliko zdravila MabThera pri ne-Hodgkinovem limfomu Klinične izkušnje s podkožno obliko zdravila MabThera pri ne-Hodgkinovem limfomu temeljijo na podatkih kliničnega preskušanja III. faze (SABRINA, BO22334) pri bolnikih s folikularnimi limfomi in preskušanja faze Ib za določanje/potrditev odmerka (SparkThera, BP22333) pri bolnikih s folikularnimi limfomi.
What MabThera looks like and contents of the pack 
Izgled zdravila MabThera in vsebina pakiranja
d) Granulomatosis with polyangiitis or microscopic polyangiitis MabThera is used for the treatment of granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids. 
granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa Zdravilo MabThera se uporablja za zdravljenje granulomatoze s poliangiitisom (prej imenovane Wegenerjeva granulomatoza) ali mikroskopskega poliangiitisa; daje se v kombinaciji s kortikosteroidi.
The overall safety profile of MabThera in rheumatoid arthritis is based on data from patients from clinical trials and from post-marketing surveillance. 
Celokupen varnostni profil zdravila MabThera pri revmatoidnem artritisu je osnovan na podatkih bolnikov iz kliničnih preskušanj in spremljanja po prihodu zdravila na trg.
In patients treated for hematological malignancies, B cell recovery began within 6 months of treatment and generally returned to normal levels within 12 months after completion of therapy, although in some patients this may take longer (up to a median recovery time of 23 months post-induction therapy). 
začele obnavljati v 6 mesecih zdravljenja, njihovo število pa se je v splošnem vrnilo v normalno stanje v 12 mesecih po končanem zdravljenju, pri nekaterih bolnikih pa je lahko trajalo dlje (mediani čas okrevanja je bil do 23 mesecev po indukcijskem zdravljenju).
The incidence of ADRs of all grades and grade 3/4 ADR was similar in elderly patients compared to younger patients (<65 years). 
Incidenca neželenih učinkov vseh stopenj ter učinkov 3. ali 4. stopnje je bila pri starejših bolnikih podobna kot pri mlajših (< 65 let).
The pharmacokinetic (PK) parameters in the anti-TNF inadequate responder population, following the same dosage regimen (2 x 1000 mg, IV, 2 weeks apart), were similar with a mean maximum serum concentration of 369 µg/mL and a mean terminal half-life of 19.2 days. 
Farmakokinetični parametri pri bolnikih, ki niso zadovoljivo odgovorili na zdravljenje z zaviralci TNF, po enakem odmerjanju (2 x 1000 mg, intravensko, v razmiku 2 tednov) so bili podobni s povprečno maksimalno koncentracijo v serumu 369 µg/ml in povprečnim končnim razpolovnim časom
Cases of hepatitis B reactivation, have been reported, the majority of which were in patients receiving MabThera in combination with cytotoxic chemotherapy. 
Poročali so o reaktivaciji virusa hepatitisa B, večinoma pri bolnikih, ki so prejemali zdravilo MabThera v kombinaciji s citotoksično kemoterapijo.
In SAWYER (BO25341), severe administration-related reactions (Grade ≥3) were reported in four patients (5%) following MabThera subcutaneous administration. 
V preskušanju SAWYER (BO25341) so hude, z dajanjem zdravila povezane reakcije (≥ 3. stopnje), zabeležili pri štirih bolnikih (5 %) po uporabi podkožne oblike zdravila MabThera.
If patients were not able to receive one full MabThera intravenous infusion dose prior to the switch, they should continue the subsequent cycles with MabThera intravenous formulation until a full intravenous dose is successfully administered. 
Če bolniki niso mogli dobiti enega polnega odmerka intravenske infuzije zdravila MabThera pred zamenjavo, morajo nadaljevati s cikli intravenske oblike zdravila MabThera, dokler uspešno ne prejmejo polnega intravenskega odmerka.
No incompatibilities between MabThera and polyvinyl chloride or polyethylene bags or infusion sets have been observed. 
Med zdravilom MabThera in vrečkami iz polivinilklorida ali polietilena ali infuzijskimi seti niso ugotovili inkompatibilnosti.
Medicinal products for the treatment of hypersensitivity reactions, e.g., epinephrine (adrenaline), antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of MabThera. 
Zdravila za zdravljenje reakcij preobčutljivosti, npr. adrenalin, antihistaminiki in glukokortikoidi, morajo biti na voljo za takojšnjo uporabo, če bi se med dajanjem zdravila MabThera pojavile alergijske reakcije.
MabThera is indicated in adults for Non-Hodgkin's lymphoma (NHL): 
Zdravilo MabThera je indicirano pri odraslih za zdravljenje ne-Hodgkinovega limfoma (NHL):
Although subgroups were small, MabThera maintenance treatment provided a significant benefit in terms of overall survival for both patients responding to CHOP and patients responding to R-CHOP, although longer follow-up is required to confirm this observation. 
Čeprav so bile podskupine majhne, je vzdrževalno zdravljenje z zdravilom MabThera pomembno povečalo korist v smislu celokupnega preživetja za bolnike, odzivne na CHOP in R-CHOP.
Table 15 Summary of efficacy by baseline autoantibody status 
Povzetek učinkovitosti glede na izhodiščno stanje protiteles
The prepared infusion solution of MabThera in 5% D-glucose solution is physically and chemically stable for 24 hours at 2 °C - 8 °C plus an additional 12 hours at room temperature. 
Pripravljena infuzijska raztopina zdravila MabThera v 5-% raztopini D-glukoze je fizikalno in kemijsko stabilna 24 ur pri temperaturi 2 do 8 °C in dodatnih 12 ur pri sobni temperaturi.
Warnings and precautions Talk to your doctor, pharmacist or nurse before you are given MabThera if: 
Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo MabThera:
MabThera was administered at a dosage of 375 mg/m2 during the first cycle one day prior to chemotherapy and at a dosage of 500 mg/m2 on day 1 of each subsequent treatment cycle. 
Zdravilo MabThera so v prvem ciklu zdravljenja dajali v odmerku 375 mg/m2 en dan pred kemoterapijo in v odmerku 500 mg/m2 1. dan vsakega naslednjega cikla zdravljenja.
In studies evaluating MabThera in combination with chemotherapy, the incidence of grade 3 and 4 cardiac arrhythmias, predominantly supraventricular arrhythmias such as tachycardia and atrial flutter/fibrillation, was higher in the R-CHOP group (14 patients, 6.9%) as compared to the CHOP group (3 patients, 1.5%). 
stopnje, predvsem supraventrikularnih aritmij, kot sta tahikardija in atrijska fibrilacija/undulacija, višja v skupini R-CHOP (14 bolnikov, 6,9 %) kot pa v skupini CHOP (3 bolniki, 1,5 %).
Infusion-related adverse reactions of all kinds have been observed in 77% of patients treated with MabThera (including cytokine release syndrome accompanied by hypotension and bronchospasm in 10% of patients) see section 4.8. 
Z infuzijo povezane neželene reakcije vseh vrst so opazili pri 77 % bolnikov, ki so se zdravili z zdravilom MabThera (vključno s sindromom sproščanja citokinov, ki sta ga spremljala hipotenzija in bronhospazem pri 10 % bolnikov), glejte poglavje 4.8.
• low numbers of platelets in the blood 
· nizko število trombocitov v krvi,
A course of MabThera consists of two 1000 mg intravenous infusions. 
Cikel zdravljenja z zdravilom MabThera je sestavljen iz dveh 1000-mg intravenskih infuzij.
The most common infections in the MabThera group were herpes simplex and zoster infections, bronchitis, urinary tract infection, fungal infection and conjunctivitis. 
Najpogostejše okužbe v skupini z zdravilom MabThera so bile okužbe z virusoma herpes simpleks in herpes zoster, bronhitis, okužbe sečil, glivične okužbe in konjunktivitis.
Patients achieving at least partial response (PR) were entered on the MabThera subcutaneous formulation maintenance therapy once every 8 weeks for 24 months. 
Bolniki, ki so dosegli vsaj delni odgovor (PR), so vstopili v vzdrževalno zdravljenje z intravensko obliko zdravila MabThera enkrat na 8 tednov za 24 mesecev.
These events were Grade 4 thrombocytopenia and Grade 3 anxiety, injection-site erythema and urticaria. 
Ti neželeni dogodki so bili: trombocitopenija 4. stopnje, anksioznost 3. stopnje, eritem na mestu injiciranja in urtikarija.
Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with MabThera. 
Pri vseh bolnikih je treba pred začetkom zdravljenja z zdravilom MabThera narediti presejalni test na virus hepatitisa B (HBV).
The rate of serious infections did not show any significant increase following multiple courses of MabThera. 
Delež resnih okužb se z nadaljnjimi cikli zdravljenja z zdravilom MabThera ni pomembno povečeval.
Marketing Authorisation Holder Roche Registration GmbH Emil-Barell-Strasse 1 
Imetnik dovoljenja za promet Roche Registration GmbH Emil-Barell-Strasse 1
No dose adjustment is required in elderly patients (aged >65 years). 
Starejšim bolnikom (> 65 let) odmerka ni treba prilagoditi.
18-months p = 0.016 
mesecev p = 0,016
In all patients subgroups (gender, age, age adjusted IPI, Ann Arbor stage, ECOG, β2 microglobulin, LDH, albumin, B symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk ratios for event-free survival and overall survival (R-CHOP compared with CHOP) were less than 0.83 and 0.95 respectively. 
V vseh podskupinah bolnikov (spol, starost, starosti prilagojen mednarodni prognostični indeks, stadij po klasifikaciji Ann Arbor, ECOG (Eastern Cooperative Oncology Group), koncentracija mikroglobulina ß2, koncentracija LDH, koncentracija albumina, B-simptomi, obsežna bolezen, ekstranodalne lokalizacije, infiltracija kostnega mozga) je bilo razmerje tveganj za preživetje brez dogodkov za R-CHOP v primerjavi s CHOP manjše kot 0,83, za skupno preživetje pa manjše kot 0,95.
A peel--off sticker is included on the vials which specifies the strength, route of administration and indication. 
Na viali je nalepka, na kateri je navedena jakost zdravila, način uporabe in indikacija.
Results from three other randomised trials using MabThera in combination with chemotherapy regimen other than CVP (CHOP, MCP, CHVP/Interferon-α) have also demonstrated significant improvements in response rates, time-dependent parameters as well as in overall survival. 
Rezultati treh drugih randomiziranih preskušanj z uporabo zdravila MabThera v kombinaciji z drugimi shemami kemoterapije (CHOP, MCP, CHVP/interferon alfa), in ne CVP, so prav tako pokazali značilna izboljšanja deležev odgovora, od časa odvisnih parametrov in celokupnega preživetja.
The pharmacokinetics of rituximab were assessed following two intravenous (IV) doses of 500 mg and 1000 mg on Days 1 and 15 in four studies. 
Farmakokinetiko rituksimaba so ocenili po dveh 500 mg in 1000 mg intravenskih odmerkih ob dnevih 1 in 15 v štirih preskušanjih.
The complete response rate after cycle 8 was 76.2 % in the R-CHOP group and 62.4 % in the CHOP group (p=0.0028). 
Po 8 ciklih zdravljenja je bil popolni odgovor v skupini R-CHOP 76,2 %, v skupini CHOP pa 62,4 % (p = 0,0028).
In clinical trials fewer than 1% (17/3189) of patients experienced a serious IRR. 
V kliničnih preskušanjih se je resna z infuzijo povezana reakcija pojavila pri manj kot 1 % bolnikov (17/3.189).
Mean terminal elimination half-life after the second infusion, following the second course, was 19 days for 2 x 500 mg dose and ranged from 21 to 22 days for the 2 x 1000 mg dose. 
Povprečni končni razpolovni čas izločanja po drugi infuziji, po drugem ciklu zdravljenja, je bil 19 dni za 2 x 500 mg odmerek ter 21 do 22 dni za 2 x 1000 mg odmerek.
In a prospective, open label, international, multi-centre, phase III trial 1193 patients with previously untreated advanced follicular lymphoma received induction therapy with R-CHOP (n=881), R-CVP (n=268) or R-FCM (n=44), according to the investigators' choice. 
V prospektivnem, odprtem, mednarodnem, multicentričnem preskušanju III. faze je 1.193 bolnikov s predhodno nezdravljenimi folikularnimi limfomi prejelo indukcijsko zdravljenje z R-CHOP (n = 881), R-CVP (n = 268) ali R-FCM (n = 44) po presoji raziskovalca.
However, because maternal IgG is excreted in human milk, and rituximab was detectable in milk from lactating monkeys, women should not breastfeed while treated with MabThera and for 12 months following MabThera treatment. 
A zaradi dejstva, da se materini IgG izločajo v materino mleko, in da so rituksimab našli v mleku doječih opic, ženske med zdravljenjem z zdravilom
body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 infusions in total). 
1400 mg enkrat na 3 mesece (z začetkom 3 mesece po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 8 aplikacij).
Ninety-nine patients were treated for induction of remission of GPA and MPA in a clinical trial with MabThera (375 mg/m2, once weekly for 4 weeks) and glucocorticoids (see section 5.1). 
Devetindevetdeset bolnikov so za indukcijo remisije GPA in MPA zdravili z zdravilom MabThera (375 mg/m2 enkrat na teden 4 tedne) in z glukokortikoidi (glejte poglavje 5.1).
In these patients the rate of clinically relevant infection while on MabThera was 6.01 per 100 patient years compared to 4.97 per 100 patient years following treatment with the biologic DMARD. 
6,01 na 100 bolnik-let, ko so se zdravili z zdravilom MabThera, v primerjavi s 4,97 na 100 bolnik-let po tem, ko so prejeli nadaljnje zdravljenje z biološkim DMARD.
Metabolism and nutrition disorders hyperglycaemia, weight decrease, peripheral oedema, face oedema, increased LDH, hypocalcaemia 
Presnovne in prehranske motnje hiperglikemija, zmanjšanje telesne mase, periferni edem, edem obraza, zvišanje LDH, hipokalciemija
Infusion related adverse reactions of all kinds have been observed in 77% of patients treated with MabThera intravenous formulation (including cytokine release syndrome accompanied by hypotension and bronchospasm in 10 % of patients) see section 4.8. 
Z infuzijo povezane neželene reakcije vseh vrst so opazili pri 77 % bolnikov, ki so se zdravili z intravensko obliko zdravila MabThera (vključno s sindromom sproščanja citokinov, ki sta ga spremljala hipotenzija in bronhospazem pri 10 % bolnikov), glejte poglavje 4.8.
• Allergic reactions that are most likely to occur during an infusion, but can occur up-to 
· alergijske reakcije, ki se najverjetneje pojavijo med infuzijo.
Ctrough values at pre-dose cycle 8 
Ctrough, vrednosti pred odmerkom 8. cikel µg/ml
When MabThera is given in combination with chemotherapy, standard dose reductions for the chemotherapeutic medicinal products should be applied. 
Če zdravilo MabThera uporabimo v kombinaciji s kemoterapijo, je treba uporabiti standardno zmanjšanje odmerkov citostatikov.
Median PFS: 28.8 Not reached p < 0.0001 
Mediana PFS: 28,8 ni doseženo p < 0,0001
The highest intravenous dose of MabThera tested in humans to date is 5000 mg (2250 mg/m2), tested in a dose escalation study in patients with CLL. 
Največji do zdaj preizkušen intravenski odmerek zdravila MabThera pri človeku je 5000 mg (2250 mg/m2), preizkušen v študiji povečevanja odmerka pri bolnikih s kronično limfocitno levkemijo.
The clinical relevance of ADA formation in MabThera-treated PV patients is unclear. 
Klinični pomen nastanka ADA pri bolnikih z navadnim pemfigusom, zdravljenih z zdravilom MabThera, ni jasen.
In the PV population, 5 (13%) patients in the MabThera group and 3 (8%) patients in the standard prednisone group had moderate disease and 33 (87%) patients in the MabThera group and 33 (92%) patients in the standard-dose prednisone group had severe disease according to disease severity defined by Harman's criteria. 
Glede na izrazitost bolezni, določeno po Harmanovih merilih, je imelo v populaciji z navadnim pemfigusom zmerno bolezen 5 (13 %) bolnikov v skupini z zdravilom MabThera in 3 (8 %) bolnikov v skupini s standardnim prednizonom, hudo bolezen pa 33 (87 %) bolnikov v skupini z zdravilom MabThera in 33 (92 %) bolnikov v skupini s standardnim prednizonom.
• A feeling of fullness or a throbbing pain behind the nose, cheeks and eyes (sinusitis), pain in the abdomen, vomiting and diarrhoea, breathing problems 
· občutek zamašenosti ali utripajoča bolečina za nosom, lici in očmi (sinuzitis), bolečina v trebuhu, bruhanje in driska, težave z dihanjem,
MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. 
Zdravilo MabThera je indicirano za zdravljenje predhodno nezdravljenih bolnikov s III. in IV. stadijem folikularnih limfomov v kombinaciji s kemoterapijo.
What MabThera is and what it is used for What you need to know before you use MabThera How to use MabThera 
Kaj je zdravilo MabThera in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo MabThera Kako uporabljati zdravilo MabThera
• lower immunity - because of lower levels of anti-bodies called “immunoglobulins” (IgG) in the blood which help protect against infection 
· zmanjšana imunost - zaradi manjše koncentracije protiteles, imenovanih imunoglobulin (IgG), v krvi; ta protitelesa pomagajo pri zaščiti proti okužbam
MabThera intravenous formulation was used at the standard dose of 375 mg/m2. 
Intravenska oblika zdravila MabThera je bila uporabljena v standardnem odmerku 375 mg/m2.
Median EFS: 36 Not reached p < 0.0001 
Mediana EFS: 36 ni doseženo p < 0,0001
The incidence of grade 3/4 blood and lymphatic adverse events was higher in elderly patients compared to younger patients (<65 years), with previously untreated or relapsed/refractory CLL. 
Incidenca neželenih dogodkov krvi in limfatičnega sistema 3. ali 4. stopnje je bila pri bolnikih s KLL, ki predhodno še niso bili zdravljeni ali pri katerih se je bolezen ponovila oziroma se na predhodno zdravljenje niso odzvali, višja pri starejših bolnikih v primerjavi z mlajšimi bolniki (< 65 let).
A longer period may be appropriate in patients with an increased risk of hypersensitivity reactions. 
Pri bolnikih, ki imajo večje tveganje za preobčutljivostne reakcije, je morda primeren daljši čas opazovanja.
The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1600 mg irrespective of the patient's body surface area. 
Priporočeni odmerek podkožne oblike zdravila MabThera za odrasle bolnike je podkožna injekcija fiksnega odmerka 1600 mg ne glede na bolnikovo telesno površino.
Hazard ratio (95% CI) 
Število bolnikov Razmerje ogroženosti (95-% CI)
The most common local cutaneous reactions in the MabThera subcutaneous arm were injection site erythema (13%), injection site pain (7%), and injection site oedema (4%). 
Najpogostejše lokalne kožne reakcije v skupini bolnikov, ki so prejemali podkožno obliko zdravila MabThera, so bile eritem na mestu injiciranja (13 %), bolečina na mestu injiciranja (7 %) in edem na mestu injiciranja (4 %).
Following two intravenous infusions of MabThera at a dose of 1000 mg, two weeks apart, the mean terminal half-life was 20.8 days (range, 8.58 to 35.9 days), mean systemic clearance was 0.23 L/day (range, 0.091 to 0.67 L/day), and mean steady-state distribution volume was 4.6 l (range, 1.7 to 7.51 L). 
Revmatoidni artritis Po dveh intravenskih infuzijah zdravila MabThera v odmerku 1000 mg v razmiku dveh tednov je bil povprečni končni razpolovni čas 20,8 dni (razpon 8,58 do 35,9 dni), povprečni sistemski očistek je bil 0,23 l/dan (razpon 0,091 do 0,67 l/dan), povprečen volumen distribucije v stanju dinamičnega ravnovesja pa 4,6 l (razpon 1,7 do 7,51 l).
The Patient information about MabThera should contain the following key elements: 
Izobraževalno gradivo za bolnika o zdravilu MabThera mora vsebovati naslednje ključne vsebine:
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
pogosti (³ 1/100 do < 1/10), občasni (³ 1/1000 do < 1/100), redki (³ 1/10.000 do < 1/1000), zelo redki
• low mood and loss of interest or enjoyment in doing things, feeling nervous 
· slabo razpoloženje in izguba zanimanja ali veselja za početje stvari, živčnost · motnje okušanja - na primer spremenjen okus stvari
• Feeling generally unwell or listless. 
· splošno slabo počutje ali brezvoljnost.
In the first-line study, after a median observation time of 48.1 months, the median PFS was 55 months in the R-FC group and 33 months in the FC group (p < 0.0001, log-rank test). 
V študiji pri bolnikih v prvi liniji zdravljenja po mediani opazovanja 48,1 meseca je bila mediana preživetja brez napredovanja bolezni 55 mesecev v skupini R-FC in 33 mesecev v skupini FC (p < 0,0001, test log-rang).